Michigan Medicine spinoff company receives the funding to commercialize the technology as its first product

ANN ARBOR, Mich. – Technology that predicts if a patient will become unstable hours before traditional vital signs is now backed with an $11.5 million Series A investment.

Fifth Eye Inc., a Michigan Medicine spinoff medical device software company started in 2017, received the investment to support research, development and commercialization of the company’s first product: the Analytic for Hemodynamic Instability (AHI).

AHI is based on technologies developed at the University of Michigan Center for Integrative Research in Critical Care (MCIRCC).